Skip to main content
Erschienen in: Intensive Care Medicine 6/2015

01.06.2015 | Editorial

Balancing the “humors” in severe sepsis: still a role for extracorporeal therapies?

verfasst von: Michael Darmon, Sean M. Bagshaw, Lui G. Forni

Erschienen in: Intensive Care Medicine | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Excerpt

The mortality and morbidity from severe sepsis continue to be a major global health problem. Although the recent data from the Protocol-Based Care for Early Septic Shock (ProCESS) study showed a lower mortality in severe sepsis than had been demonstrated some 10 years previously, the mortality remains unacceptably high [1, 2]. The pathogenesis of sepsis is complex, leading to the production of a wide range of inflammatory mediators, which propagate the host response to infection leading to the clinical syndrome of septic shock with multi-organ involvement. At present, treatment relies predominantly on source control, adequate early antimicrobials and organ support where necessary with little effective, targeted therapy [35]. …
Literatur
1.
Zurück zum Zitat Investigators ProCESS, Yealy DM, Kellum JA et al (2014) A randomized trial of protocol-based care for early septic shock. N Engl J Med 370:1683–1693CrossRef Investigators ProCESS, Yealy DM, Kellum JA et al (2014) A randomized trial of protocol-based care for early septic shock. N Engl J Med 370:1683–1693CrossRef
2.
Zurück zum Zitat Rivers E, Nguyen B, Havstad S et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377PubMedCrossRef Rivers E, Nguyen B, Havstad S et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377PubMedCrossRef
3.
Zurück zum Zitat Parmar A, Langenberg C, Wan L et al (2009) Epidemiology of septic acute kidney injury. Curr Drug Targets 10:1169–1178PubMedCrossRef Parmar A, Langenberg C, Wan L et al (2009) Epidemiology of septic acute kidney injury. Curr Drug Targets 10:1169–1178PubMedCrossRef
4.
Zurück zum Zitat Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228PubMedCrossRef Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228PubMedCrossRef
5.
Zurück zum Zitat Levy MM, Rhodes A, Phillips GS et al (2014) Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study. Intensive Care Med 40:1623–1633PubMedCrossRef Levy MM, Rhodes A, Phillips GS et al (2014) Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study. Intensive Care Med 40:1623–1633PubMedCrossRef
6.
Zurück zum Zitat De Vriese AS, Colardyn FA, Philippé JJ et al (1999) Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 10:846–853PubMed De Vriese AS, Colardyn FA, Philippé JJ et al (1999) Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 10:846–853PubMed
7.
Zurück zum Zitat De Vriese AS, Vanholder RC, Pascual M et al (1999) Can inflammatory cytokines be removed efficiently by continuous renal replacement therapies? Intensive Care Med 25:903–910PubMedCrossRef De Vriese AS, Vanholder RC, Pascual M et al (1999) Can inflammatory cytokines be removed efficiently by continuous renal replacement therapies? Intensive Care Med 25:903–910PubMedCrossRef
8.
Zurück zum Zitat Payen D, Mateo J, Cavaillon JM et al (2009) Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 37:803–810PubMedCrossRef Payen D, Mateo J, Cavaillon JM et al (2009) Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 37:803–810PubMedCrossRef
9.
Zurück zum Zitat Joannes-Boyau O, Honoré PM, Perez P, Bagshaw SM et al (2013) High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med 39:1535–1546PubMedCrossRef Joannes-Boyau O, Honoré PM, Perez P, Bagshaw SM et al (2013) High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med 39:1535–1546PubMedCrossRef
10.
Zurück zum Zitat Zhou F, Peng Z, Murugan R, Kellum JA (2013) Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit Care Med 41:2209–2220PubMedCentralPubMedCrossRef Zhou F, Peng Z, Murugan R, Kellum JA (2013) Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit Care Med 41:2209–2220PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Iwagami M, Yasunaga H, Doi K et al (2014) Postoperative polymyxin B hemoperfusion and mortality in patients with abdominal septic shock: a propensity-matched analysis. Crit Care Med 42:1187–1193PubMedCrossRef Iwagami M, Yasunaga H, Doi K et al (2014) Postoperative polymyxin B hemoperfusion and mortality in patients with abdominal septic shock: a propensity-matched analysis. Crit Care Med 42:1187–1193PubMedCrossRef
12.
Zurück zum Zitat Cruz DN, Perazella MA, Bellomo R et al (2007) Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 11:R47PubMedCentralPubMedCrossRef Cruz DN, Perazella MA, Bellomo R et al (2007) Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 11:R47PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Cruz DN, Antonelli M, Fumagalli R et al (2009) Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301:2445–2452PubMedCrossRef Cruz DN, Antonelli M, Fumagalli R et al (2009) Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301:2445–2452PubMedCrossRef
14.
Zurück zum Zitat Payen DM, Guilhot J, Launey Y et al (2015) Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. doi:10.1007/s00134-015-3751-z Payen DM, Guilhot J, Launey Y et al (2015) Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. doi:10.​1007/​s00134-015-3751-z
15.
Zurück zum Zitat Nakamura T, Ebihara I, Shoji H et al (1999) Treatment with polymyxin B-immobilized fiber reduces platelet activation in septic shock patients: decrease in plasma levels of soluble P-selectin, platelet factor 4 and beta-thromboglobulin. Inflamm Res 48:171–175PubMedCrossRef Nakamura T, Ebihara I, Shoji H et al (1999) Treatment with polymyxin B-immobilized fiber reduces platelet activation in septic shock patients: decrease in plasma levels of soluble P-selectin, platelet factor 4 and beta-thromboglobulin. Inflamm Res 48:171–175PubMedCrossRef
16.
Zurück zum Zitat Nemoto H, Nakamoto H, Okada H et al (2001) Newly developed immobilized polymyxin B fibers improve the survival of patients with sepsis. Blood Purif 19:361–368 (discussion 368–369)PubMedCrossRef Nemoto H, Nakamoto H, Okada H et al (2001) Newly developed immobilized polymyxin B fibers improve the survival of patients with sepsis. Blood Purif 19:361–368 (discussion 368–369)PubMedCrossRef
17.
Zurück zum Zitat Vincent JL, Laterre PF, Cohen J et al (2005) A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 23:400–405PubMedCrossRef Vincent JL, Laterre PF, Cohen J et al (2005) A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 23:400–405PubMedCrossRef
Metadaten
Titel
Balancing the “humors” in severe sepsis: still a role for extracorporeal therapies?
verfasst von
Michael Darmon
Sean M. Bagshaw
Lui G. Forni
Publikationsdatum
01.06.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Intensive Care Medicine / Ausgabe 6/2015
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-015-3801-6

Weitere Artikel der Ausgabe 6/2015

Intensive Care Medicine 6/2015 Zur Ausgabe

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.